☆ 4.5 Article

Matched tissue and liquid biopsies for advanced non-small cell lung cancer patients A potentially indispensable complementary approach

TRANSLATIONAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid)

Akira Sugimoto et al.

Summary: In this study, concordance between plasma cfDNA and tissue-based sequencing for oncogenic driver detection in NSCLC was evaluated. The results showed that plasma cfDNA sequencing had relatively high sensitivity for detecting gene mutations, but low sensitivity for gene fusions and MET exon 14 skipping, compared to tissue-based sequencing.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Review Cell Biology

The use of minimal residual disease in thoracic oncology: Gaps between promises and the on-the-ground reality of daily practice

Paul Hofman et al.

Summary: The assessment of minimal residual disease (MRD) from blood samples has potential in optimizing patient care for resected non-small cell lung carcinoma (NSCLC). Evaluating MRD status can improve overall survival for early stage NSCLC patients and reduce the toxic effects and financial burden of treatment. Clinical trials have examined MRD in early stage NSCLC, highlighting the need to bridge the gap between research and routine practice. Further action is necessary to assess the relevance of MRD detection in interventional clinical studies, comparing different techniques, time points, and cutoffs. This article investigates and provides recommendations for optimizing MRD evaluation in NSCLC.

CYTOPATHOLOGY (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

Christopher Abbosh et al.

Summary: Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells after surgery. A study involving a large number of early-stage non-small-cell lung cancer (NSCLC) patients found that preoperative absence of ctDNA detection is associated with better clinical outcome. Postoperative plasma analysis revealed ctDNA detection in 25% of patients within 120 days after surgery, and 49% of patients who experienced clinical relapse were identified.

NATURE (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

Zoe June F. Assaf et al.

Summary: Researchers have found that longitudinal monitoring of circulating tumor DNA (ctDNA) can predict the survival of patients with non-small-cell lung cancer (NSCLC), improving risk stratification and treatment selection. A machine learning model using ctDNA metrics accurately predicts survival in two phase 3 trials.

NATURE MEDICINE (2023)

添加到收藏夹

Article Critical Care Medicine

Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer

Siwei Wang et al.

Summary: In this study, an accurate and affordable approach for early-stage lung cancer detection was established by integrating cfDNA fragmentomics and machine learning models. The stacked ensemble model achieved superior sensitivity for detecting early-stage lung cancer, which could promote early diagnosis and benefit more patients.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

添加到收藏夹

Review Oncology

Liquid Biopsy Screening for Early Detection of Lung Cancer: Current State and Future Directions

William Zhu et al.

Summary: Liquid biopsy (LB) is a clinically utilized tool to detect minute amounts of genetic material or protein shed by cancer cells, and can be used as a noninvasive precision oncology tool for cancer therapy guidance, tumor cell detection, and multi-cancer screening. It holds great promise in improving early lung cancer detection among all populations at risk.

CLINICAL LUNG CANCER (2023)

添加到收藏夹

Article Hematology

Association of clonal hematopoiesis with chronic obstructive pulmonary disease

Peter G. Miller et al.

Summary: Somatic mutations in blood cells are associated with the development and severity of chronic obstructive pulmonary disease (COPD), independent of age and smoking.

BLOOD (2022)

添加到收藏夹

Article Oncology

Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer

Ray D. Page et al.

Summary: Liquid biopsy provides a fast and noninvasive method for genomic profiling in patients with newly diagnosed, advanced NSCLC, allowing the identification of NCCN-recommended biomarkers and informing first-line therapy options. This study demonstrates that liquid biopsy achieves similar treatment outcomes compared to tissue-genotyping, while offering a significantly faster initiation of targeted therapy. Liquid biopsy can be a valuable tool in guiding targeted therapy decisions at the time of diagnosis in advanced disease.

CLINICAL LUNG CANCER (2022)

添加到收藏夹

Review Oncology

Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications

Daniel Kazdal et al.

Summary: Targeted therapy is preferred over chemotherapy and immunotherapy for actionable gene fusions in late-stage non-small cell lung carcinoma (NSCLC) due to its superior efficacy and tolerability. Testing for ALK, ROS1, NTRK, and RET gene fusions is now mandatory for all newly diagnosed advanced non-squamous NSCLC patients. RNA next-generation sequencing (NGS) or combined DNA/RNA NGS is the preferred method for detecting gene fusions. Recent advancements have led to the discovery of new gene fusions, necessitating the development of comprehensive detection methods and promising therapies.

GENES CHROMOSOMES & CANCER (2022)

添加到收藏夹

Review Oncology

Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent

Bruna Pellini et al.

Summary: Circulating tumor DNA minimal residual disease is a powerful biomarker with the potential to improve survival outcomes for non-small-cell lung cancer. Although the current studies are limited in size, largely retrospective, and without thorough prospective clinical validation, the detection of ctDNA minimal residual disease has shown good sensitivity and specificity at the first post-treatment timepoint, and improved performance in surveillance.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways

Lukas Kraehenbuehl et al.

Summary: The discovery and clinical implementation of immune-checkpoint inhibitors like CTLA4, PD-1, and PD-L1 have significantly improved outcomes for patients with advanced-stage cancers. However, a majority of patients do not respond to these agents, emphasizing the need for further research into alternative immunomodulatory pathways and targeting tumor metabolism to enhance treatment efficacy.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Molecular Pathology of Lung Cancer

James J. Saller et al.

Summary: This article provides an overview of the molecular pathology of lung cancer, including the most significant molecular alterations of the genome, transcriptome, and epigenome. It discusses the insights gained from the use of next-generation sequencing (NGS) in lung cancer research and explores concepts such as intertumor heterogeneity, intratumor heterogeneity, tumor mutational burden, and liquid biopsy. Additionally, it highlights the importance of molecular pathology in refining the understanding of histologic phenotypes of non-small-cell lung cancer (NSCLC) and the biology of small-cell lung cancer.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2022)

添加到收藏夹

Article Oncology

Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer

D. Gale et al.

Summary: Detection of ctDNA using sensitive patient-specific assays after initial treatment has the potential to identify early-stage NSCLC patients who may benefit from further therapeutic intervention.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer

Fiorella Calabrese et al.

Summary: Patients with non-small cell lung cancer, especially adenocarcinomas, often have specific genetic mutations that can be targeted for therapy. While targeted treatments have improved patient outcomes, some patients may develop resistance to treatment. This review discusses the transformation of lung cancer into different histotypes and molecular mechanisms of resistance, providing a comprehensive overview of the topic.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Oncology

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

Diego de Miguel-Perez et al.

Summary: This study evaluated the use of extracellular vesicle PD-L1 expression as a biomarker for predicting durable treatment response and survival in non-small cell lung cancer (NSCLC) patients receiving immune-checkpoint inhibitors (ICIs). The results showed that an increase in extracellular vesicle PD-L1 was observed in non-responders compared to responders and was an independent biomarker for shorter progression-free survival and overall survival. In contrast, tissue PD-L1 expression, the commonly used biomarker, was not predictive for durable response or survival.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer

Wanyuan Cui et al.

Summary: This study demonstrates that blood-first cfDNA-NGS can improve the breadth and rapidity of detecting actionable variants in patients with advanced-stage lung cancer, leading to timely treatment decisions.

LUNG CANCER (2022)

添加到收藏夹

Article Oncology

Analytical validation of automated multiplex chromogenic immunohistochemistry for diagnostic and predictive purpose in non-small cell lung cancer

Marius Ilie et al.

Summary: This study optimized two automated four-plex immunohistochemistry (mIHC) assays and evaluated the repeatability and concordance of cell density assessment. After optimization, the mIHC assay showed sensitive and repeatable assessment of eight diagnostic and predictive biomarkers for non-small cell lung cancer (NSCLC), providing a reliable method for clinical decision-making.

LUNG CANCER (2022)

添加到收藏夹

Article Oncology

Comparative study on the mutation spectrum of tissue DNA and blood ctDNA in with non-small cell cancer

Meichun Zhang et al.

Summary: This study utilized targeted next-generation sequencing technology to detect genetic mutations in tissue DNA and ctDNA samples of patients with advanced lung cancer. The results showed that both tissue DNA and ctDNA samples could detect genetic mutations and were consistent. Therefore, ctDNA detection may be helpful for the clinical diagnosis and treatment of lung cancer patients.

TRANSLATIONAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France)

Marius Ilie et al.

Summary: Due to the increasing complexity of genomic alterations in non-squamous non-small cell lung carcinoma (NS-NSCLC), it is challenging to evaluate biomarkers using sequential analyses. This study reports the development of an optimal workflow for genomic alteration assessment in routine clinical practice using ultra-fast next generation sequencing. The results demonstrate high concordance with gold standard methods and a quick turnaround time, even with a small amount of nucleic acids.

CANCERS (2022)

添加到收藏夹

Article Oncology

Application of an Ultrasensitive NGS-Based Blood Test for the Diagnosis of Early-Stage Lung Cancer: Sensitivity, a Hurdle Still Difficult to Overcome

Malaika Van der Linden et al.

Summary: Currently, the diagnosis of lung cancer relies on tissue biopsies, which are invasive and not always obtainable. This study investigated the potential of liquid biopsy, using targeted deep sequencing and imaging, for the early detection of lung cancer. By analyzing cell-free DNA mutations in plasma samples, early-stage lung cancer patients can be almost perfectly differentiated from controls. However, the sensitivity of liquid biopsy for early-stage lung cancer detection is limited by the low variant allele fraction of somatic variants.

CANCERS (2022)

添加到收藏夹

Review Oncology

Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer

E. Heitzer et al.

Summary: This paper reviews the challenges and current applications of ctDNA mutation testing in metastatic non-small cell lung cancer (NSCLC). The study finds that ctDNA mutation testing has potential value in complementing tissue biopsy, identifying resistance mechanisms, and assisting in therapy selection. It also provides insights into potential targets that may have been missed on tissue biopsy.

ESMO OPEN (2022)

添加到收藏夹

Article Oncology

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

J. Pascual et al.

Summary: Circulating tumour DNA (ctDNA) assays conducted on plasma are proving to be valuable tools for identifying actionable mutations in patients with advanced cancer and for detecting molecular residual disease or relapse in early-stage cancer. However, tissue-based testing is still preferred due to the limitations of ctDNA assays.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung

Edgardo S. Santos et al.

Summary: Squamous cell carcinoma (SCC) of the lung has a different molecular profile compared to adenocarcinoma, making it difficult to treat due to the lack of targeted therapies. As immune checkpoint inhibitors become first-line treatments for non-small cell lung cancer (NSCLC), there is an urgent need for effective second-line options following immunotherapy. Prospective clinical data is lacking for appropriate treatment decisions, but real-world data suggest that ramucirumab plus docetaxel should be evaluated in this setting. Afatinib, approved as a second-line option for SCC patients progressing on platinum-based chemotherapy, may also be considered after immunochemotherapy combinations. Docetaxel, gemcitabine, and platinum-based chemotherapy may be options for some patients, but overall, there are limited choices for second-line treatment after immunotherapy. Therefore, efforts to define the molecular profile of lung SCC and identify relevant targeted therapies are necessary. Genomic testing is essential to identify patients who may benefit from existing targeted agents or clinical trials. Additional prospective data are urgently needed to assess potential second-line regimens following immunotherapy.

CLINICAL LUNG CANCER (2022)

添加到收藏夹

Letter Oncology

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

A. Bayle et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer

Fang-Qi Li et al.

Summary: Circulating tumor DNA can be used to evaluate efficacy, recurrence risk, and treatment choices for lung cancer patients. However, there are barriers in terms of detection sensitivity and consistent detection times.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

添加到收藏夹

Article Oncology

P2.14-01 Clinical Utility of Reflex to Tissue-based Comprehensive Genomic Profiling (CGP) After Negative Liquid Biopsy (LBx) in NSCLC

H. Husain et al.

Journal of Thoracic Oncology (2022)

添加到收藏夹

Article Oncology

The evolving role of liquid biopsy in lung cancer

Umberto Malapelle et al.

Summary: Liquid biopsy has brought about a revolutionary approach in managing cancer patients, especially when solid tissue biopsies are insufficient. It not only predicts cancer markers but also facilitates comprehensive tumor genotyping, identification of emergent resistance mechanisms, monitoring of minimal residual disease, early cancer detection, and cancer interception.

LUNG CANCER (2022)

添加到收藏夹

Article Oncology

Identification of a circulating immunological signature predictive of response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

Wassila Khatir et al.

CLINICAL AND TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Review Health Care Sciences & Services

Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing

Nina Pujol et al.

Summary: Molecular diagnosis of lung cancer is a constantly evolving field that requires repeated testing to establish accurate molecular diagnosis and track disease evolution. The emergence of next-generation sequencing (NGS) has greatly facilitated molecular profiling in lung cancer.

JOURNAL OF PERSONALIZED MEDICINE (2022)

添加到收藏夹

Article Oncology

Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy

Miguel Garcia-Pardo et al.

Summary: Liquid biopsy in the initial diagnostic workup of patients with suspected advanced NSCLC can lead to faster molecular results and shorten time to treatment.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Plasma-first: accelerating Lung cancer diagnosis and molecular profiling through liquid biopsy

Miguel Garcia-Pardo et al.

Summary: This study explored the use of plasma circulating-tumor DNA testing in the initial diagnostic workup of patients with suspected advanced lung cancer and found that it could lead to faster molecular results and shorten time to treatment.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

添加到收藏夹

Article Health Care Sciences & Services

Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring

Denis Horgan et al.

Summary: Liquid biopsy is a minimally invasive method aimed at detecting circulating tumor-derived components in body fluids, providing an alternative to tissue biopsies for cancer diagnosis confirmation. This paper explores the support provided by regulatory, policy, and governance frameworks for implementing LB technology in healthcare systems.

HEALTHCARE (2022)

添加到收藏夹

Article Oncology

cfDNA methylome profiling for detection and subtyping of small cell lung cancers

Francesca Chemi et al.

Summary: This article describes a workflow for genome-wide DNA methylation profiling that can be used to detect circulating cell-free DNA in patients with small cell lung cancer, and is correlated with survival outcomes. Additionally, this method can also differentiate between different SCLC subtypes.

NATURE CANCER (2022)

添加到收藏夹

Article Oncology

Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer

Steven Olsen et al.

Summary: Comprehensive genomic profiling can guide targeted therapy for advanced NSCLC patients and improve clinical outcomes.

CURRENT ONCOLOGY (2022)

添加到收藏夹

Article Pathology

Impact of the new European Union In Vitro Diagnostics Regulation on the practice of hospital diagnostic laboratories

Audrey M. M. Hermans et al.

Summary: The study investigated the current use of companion diagnostics (CDx) in hospital practice in the Netherlands, focusing on factors influencing the choice between in-house or commercial CDx. Factors such as costs, convenience, complexity of application, and compatibility with existing workflows were found to play key roles. Concerns were raised about potential increased costs, administrative work, and decreased quality with the introduction of the In Vitro Diagnostics Regulation 2017/746 (IVDR).

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2022)

添加到收藏夹

Review Biochemical Research Methods

The Diagnostic Accuracy of Liquid Biopsy in EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis of 40 Studies

Naiqun Wang et al.

Summary: Liquid biopsy showed better specificity in detecting EGFR mutations in NSCLC patients, with tissue biopsy still necessary for patients with negative blood biopsy results due to its lower sensitivity. EGFR mutations were associated with improved progression-free survival compared to wild type in both tissue and blood detection.

SLAS TECHNOLOGY (2021)

添加到收藏夹

Article Oncology

Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency

Jean G. Bustamante Alvarez et al.

Summary: The next-generation sequencing of circulating cell-free DNA (cfDNA) can identify molecular alterations in non-small-cell lung cancer, leading to appropriate targeted treatments when tissue is insufficient. This retrospective study found that 10% of patients who could not obtain tissue diagnosis initiated targeted therapy based solely on identification of actionable mutations by cfDNA testing.

CLINICAL LUNG CANCER (2021)

添加到收藏夹

Editorial Material Oncology

Small cell lung cancer enters the era of precision medicine

Kristopher K. Frese et al.

Summary: Gay et al. present a molecular classification of small cell lung cancers in Cancer Cell, extending previous studies on personalized treatments. Their identification of an "inflamed" subtype suggests potential susceptibility to immunotherapy after acquired chemoresistance.

CANCER CELL (2021)

添加到收藏夹

Review Oncology

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Christian Rolfo et al.

Summary: Although precision medicine has had mixed impact on clinical management of patients with advanced-stage cancer overall, the advances have been dramatic for NSCLC, specifically lung adenocarcinoma, due to genomic complexity and increasing number of druggable oncogene drivers. Liquid biopsy serves as a practical alternative source for investigating tumor-derived somatic alterations, offering a minimally invasive approach for selecting targeted therapies. The most extensively studied methodology is plasma circulating tumor DNA, which has wide adoption as an alternative to tissue tumor genotyping, particularly in solid tumors like NSCLC.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

ALK-rearranged squamous cell carcinoma of the lung

Qiyi Meng et al.

Summary: ALK rearrangement in squamous cell carcinoma of the lung is rare, with patients typically lacking sufficient clinical data. This study identified eight cases of SCC with ALK rearrangement, with two patients receiving crizotinib as second-line therapy, one showing stable disease for six months and the other showing disease progression with a shorter progression-free survival. Overall, ALK-inhibitor therapy benefited ALK-rearranged SCC patients, particularly non-smokers identified through IHC+/FISH+.

THORACIC CANCER (2021)

添加到收藏夹

Article Oncology

High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program

Sehhoon Park et al.

Summary: This study analyzed the concordance of actionable genomic alterations in non-small cell lung cancer patients detected through circulating tumor DNA (ctDNA) and tissue sequencing. The results showed that ctDNA testing can identify additional actionable genomic alterations beyond tissue testing.

CANCER (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Ultrasound-guided transthoracic needle biopsy of the lung: sensitivity and safety variables

Simon Lemieux et al.

Summary: This study found that factors such as pleural contact length, lesion size, and core needle diameter are associated with the sensitivity and complication rates of ultrasound-guided transthoracic needle biopsy (US-TTNB).

EUROPEAN RADIOLOGY (2021)

添加到收藏夹

Review Oncology

Next-Generation Sequencing with Liquid Biopsies from Treatment-Naive Non-Small Cell Lung Carcinoma Patients

Paul Hofman

Summary: Liquid biopsy (LB) has become the only option to detect molecular targets for first-line treatment in treatment-naive NSCLC patients. Despite not being commonly used in diagnosis currently, Next-Generation Sequencing (NGS) shows the most promise for assessing genetic abnormalities.

CANCERS (2021)

添加到收藏夹

Article Oncology

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

E. A. Klein et al.

Summary: This study confirmed the feasibility of using the refined MCED test version as a screening tool, demonstrating high specificity and accuracy in predicting CSO, and detecting signals of various cancers.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer

Misako Nagasaka et al.

Summary: Liquid biopsy has become a valuable diagnostic tool for advanced NSCLC, with ctDNA analysis being a key method for identifying targetable mutations. Monitoring ctDNA in plasma can help assess treatment response and residual disease burden, and new methods like miRNA and lncRNA are also being explored for their potential in NSCLC diagnosis and monitoring.

MOLECULAR CANCER (2021)

添加到收藏夹

Article Oncology

Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay

Simon Heeke et al.

Summary: The study evaluated a novel RT-PCR-based detection method for ALK rearrangements in plasma of NSCLC patients, demonstrating limited sensitivity but high specificity at baseline and disease progression. Therefore, this detection method could potentially be considered for selecting patients for ALK-targeted therapy when tissue samples are lacking.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer

Ramon Palmero et al.

Summary: This study found that comprehensive cfDNA testing is as effective as tissue testing in detecting guideline-recommended biomarkers in aNSCLC. First-line therapy based on cfDNA produced similar outcomes to tissue-based testing, highlighting the clinical utility of comprehensive cfDNA genotyping as an initial modality in treatment-naive aNSCLC patients.

JCO PRECISION ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis

Defeng Kong et al.

Summary: A meta-analysis of 20 articles found that the expression of PD-L1 on CTCs in the peripheral blood of cancer patients is associated with poor prognosis, with patients expressing PD-L1 having a shorter survival time.

ONCOIMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France)

Simon Heeke et al.

CLINICAL LUNG CANCER (2020)

添加到收藏夹

Article Anatomy & Morphology

Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance

Theresa A. Boyle et al.

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2020)

添加到收藏夹

Article Pathology

EGFR mutation exists in squamous cell lung carcinoma

Alvin Ho-Kwan Cheung et al.

PATHOLOGY (2020)

添加到收藏夹

Editorial Material Oncology

Molecular testing for lung adenocarcinoma: Is it time to adopt a plasma-first approach?

Maisam Makarem et al.

CANCER (2020)

添加到收藏夹

Article Oncology

Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma

Kartik Anand et al.

CLINICAL LUNG CANCER (2020)

添加到收藏夹

Review Oncology

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

Marco Russano et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Review Respiratory System

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting

Mariantonia Nacchio et al.

JOURNAL OF THORACIC DISEASE (2020)

添加到收藏夹

Article Critical Care Medicine

Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study

Charles-Hugo Marquette et al.

Lancet Respiratory Medicine (2020)

添加到收藏夹

Review Oncology

Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectives

Paul Hofman et al.

CANCER CYTOPATHOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

Barzin Y. Nabet et al.

CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

Jordi Remon et al.

PLOS ONE (2020)

添加到收藏夹

Review Oncology

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

F. Mosele et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling

Angel Qin et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions

Young Kwang Chae et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Review Respiratory System

The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients

Paul Hofman

JOURNAL OF THORACIC DISEASE (2019)

添加到收藏夹

Review Oncology

Lung Cancer Screening, towards a Multidimensional Approach: Why and How?

Jonathan Benzaquen et al.

CANCERS (2019)

添加到收藏夹

Article Oncology

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer

Natasha B. Leighl et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Review Oncology

Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?

P. Hofman et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts

Daniel Kazdal et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Review Multidisciplinary Sciences

Clonal hematopoiesis in human aging and disease

Siddhartha Jaiswal et al.

SCIENCE (2019)

添加到收藏夹

Article Oncology

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

J. Zugazagoitia et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer

Charu Aggarwal et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Medical Laboratory Technology

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Neal I. Lindeman et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting

Carolyn J. Presley et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing

Qiaomei Guo et al.

MOLECULAR CANCER (2018)

添加到收藏夹

Review Oncology

Will liquid biopsies improve outcomes for patients with small-cell lung cancer?

Fiona Blackhall et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing

Thomas P. Slavin et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer

M. Ilie et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?

Alexander T. Falk et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2017)

添加到收藏夹

Review Pathology

PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?

Paul Hofman

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2017)

添加到收藏夹

Article Oncology

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling

Aadel A. Chaudhuri et al.

CANCER DISCOVERY (2017)

添加到收藏夹

Article Oncology

Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients

Marius Ilie et al.

ONCOTARGET (2017)

添加到收藏夹

Review Oncology

Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology

Paul Hofman

CANCERS (2017)

添加到收藏夹

Article Oncology

Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients

Yuebi Hu et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

Martin E. Gutierrez et al.

CLINICAL LUNG CANCER (2017)

添加到收藏夹

Article Oncology

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

Chris Karlovich et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Article Oncology

Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?

Charles Lim et al.

JOURNAL OF THORACIC ONCOLOGY (2016)

添加到收藏夹

Review Pathology

Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients

Marius Ilie et al.

VIRCHOWS ARCHIV (2016)

添加到收藏夹

Article Oncology

Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer

C. Lim et al.

ANNALS OF ONCOLOGY (2015)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.